Paloma Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Paloma Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,625	Closed	-$346K	–	2650
2020 Q2	$346K	Buy	+13,625	New	+$294K	0.01%	1410
2017 Q3	–	Sell	-160,000	Closed	-$507K	–	2572
2017 Q2	$507K	Hold	160,000	–	–	0.01%	1539
2017 Q1	$544K	Buy	160,000 +53,131	+50%	+$150K	0.01%	1554
2016 Q4	$308K	Buy	+106,869	New	+$380K	﹤0.01%	1690
2016 Q3	–	Sell	-60,979	Closed	-$183K	–	2231
2016 Q2	$183K	Buy	+60,979	New	+$250K	﹤0.01%	1988

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Paloma Partners's DRNA Position: Q3 2020 in Review

Paloma Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 13,625 shares — an estimated $346K sold.

Paloma Partners first reported a position in DRNA in Q2 2016 and held it in 5 quarters. The position peaked at $544K in Q1 2017. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

Paloma Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 13,625 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $346K.
Paloma Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2016 and held it in 5 quarters.
Paloma Partners's Dicerna Pharmaceuticals, Inc. position peaked at $544K in Q1 2017.
172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.